Pulse Biosciences Reports Exceptional 6- and 12-Month Data from nPulse Cardiac Catheter Feasibility Study
Summary
Pulse Biosciences released compelling clinical data for its nPulse Cardiac Catheter, demonstrating high procedural success and a strong safety profile in treating atrial fibrillation, positioning the company for a pivotal study.
Key Events
-
Strong Clinical Efficacy
The nPulse Cardiac Catheter achieved 100% procedural success in evaluable patients at 6 months (75/75) and 96% at one year (45/47) in its first-in-human feasibility study for atrial fibrillation.
-
Favorable Safety Profile
The study reported a low 1.3% (2/150) serious adverse event rate related to the primary safety endpoint, indicating a strong safety profile for the device.
-
Efficient Procedure Times
The nPulse system demonstrated rapid procedure times, with average total procedure and fluoroscopy times of 65 and 9.8 minutes, respectively, highlighting workflow efficiency.
-
Advancing Towards Pivotal Study
The company is poised to initiate its pivotal IDE study, a crucial step towards potential regulatory approval and commercialization in the U.S. and Europe.
Analysis
Pulse Biosciences announced highly positive 6- and 12-month data from its nPulse Cardiac Catheter first-in-human feasibility study for atrial fibrillation. The reported 100% procedural success at 6 months and 96% at 12 months, coupled with a low 1.3% serious adverse event rate, significantly de-risks the nPulse system. These strong results, presented at a major cardiology symposium, validate the technology's safety and effectiveness and pave the way for the upcoming pivotal IDE study, marking a critical step towards potential commercialization and addressing a substantial market need.
At the time of this filing, PLSE was trading at $14.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $927.7M. The 52-week trading range was $12.56 to $25.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.